Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
aTyr Pharma participates in a conference call with Roth Capital » 09:25
06/30/20
06/30
09:25
06/30/20
09:25
LIFE

aTyr Pharma

$4.57 /

+0.21 (+4.82%)

Biotechnology Analyst…

Biotechnology Analyst Jallah holds a conference call with CEO Shukla, who will provide details on aTyr's ATYR1923 and COVID-19 on June 30 at 10 am hosted by Roth Capital.

ShowHide Related Items >><<
LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

06/18/20 Roth Capital
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

  • 06
    Feb
LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

Conference/Events
aTyr Pharma participates in a conference call with Roth Capital » 04:55
06/30/20
06/30
04:55
06/30/20
04:55
LIFE

aTyr Pharma

$4.57 /

+0.21 (+4.82%)

Biotechnology Analyst…

Biotechnology Analyst Jallah holds a conference call with CEO Shukla, who will provide details on aTyr's ATYR1923 and COVID-19 on June 30 at 10 am hosted by Roth Capital.

ShowHide Related Items >><<
LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

06/18/20 Roth Capital
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

  • 06
    Feb
LIFE aTyr Pharma
$4.57 /

+0.21 (+4.82%)

Conference/Events
aTyr Pharma participates in a conference call with Roth Capital » 09:44
06/26/20
06/26
09:44
06/26/20
09:44
LIFE

aTyr Pharma

$4.51 /

+ (+0.00%)

Biotechnology Analyst…

Biotechnology Analyst Jallah holds a conference call with CEO Shukla, who will provide details on aTyr's ATYR1923 and COVID-19 on June 30 at 10 am hosted by Roth Capital.

ShowHide Related Items >><<
LIFE aTyr Pharma
$4.51 /

+ (+0.00%)

LIFE aTyr Pharma
$4.51 /

+ (+0.00%)

06/18/20 Roth Capital
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
LIFE aTyr Pharma
$4.51 /

+ (+0.00%)

  • 06
    Feb
LIFE aTyr Pharma
$4.51 /

+ (+0.00%)

Hot Stocks
aTyr Pharma presents preclinical research on NRP2 antibody effects » 08:30
06/22/20
06/22
08:30
06/22/20
08:30
LIFE

aTyr Pharma

$4.21 /

+0.27 (+6.85%)

aTyr Pharma announced a…

aTyr Pharma announced a poster and audio presentation at the 2020 American Association for Cancer Research Virtual Annual Meeting II, which is being held June 22 - 24, 2020. The poster is available for browsing on the AACR website from June 22 - 24, 2020. The poster presents findings from a preclinical study, conducted in collaboration with Dr. Arthur M. Mercurio and his lab at the University of Massachusetts Medical School, demonstrating that aTyr has generated a panel of anti-human NRP2 monoclonal antibodies that have the potential to be developed for the clinical management of solid tumors. Importantly, these antibodies showed differential binding to specific domains of NRP2, selectively inhibiting binding of either VEGF or Sema3F. In combination with chemotherapy, an antibody blocking the VEGF binding site of NRP2 was effective in preventing mammosphere formation in organoids derived from triple-negative breast cancer (TNBC) patients. Expression of NRP2 has been shown to be high in TNBC tumors and has been linked to worsened outcomes for patients. These results suggest that antibodies targeting NRP2 could potentially be effective in certain types of solid tumors, including breast cancer.

ShowHide Related Items >><<
LIFE aTyr Pharma
$4.21 /

+0.27 (+6.85%)

LIFE aTyr Pharma
$4.21 /

+0.27 (+6.85%)

06/18/20 Roth Capital
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
LIFE aTyr Pharma
$4.21 /

+0.27 (+6.85%)

LIFE aTyr Pharma
$4.21 /

+0.27 (+6.85%)

Recommendations
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital » 11:46
06/18/20
06/18
11:46
06/18/20
11:46
LIFE

aTyr Pharma

$3.90 /

+0.015 (+0.39%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah noted that aTyr issued a press release to highlight recently published third-party articles. The research, "when extrapolated, suggest that ATYR-1923 could prevent coronavirus cell entry," said Jallah, who believes that these findings, paired with additional literature findings, support increased odds of ATYR-1923 resulting in a therapeutic benefit in COVID-19 patients. She recommends that "investors buy on this update" and maintains a Buy rating on aTyr shares.

ShowHide Related Items >><<
LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
03/02/20 Oppenheimer
aTyr Pharma initiated with an Outperform at Oppenheimer
LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

Hot Stocks
aTyr Pharma highlights research implicating neuropilin pathway in COVID-19 » 11:43
06/18/20
06/18
11:43
06/18/20
11:43
LIFE

aTyr Pharma

$3.90 /

+0.015 (+0.39%)

Last night, aTyr Pharma…

Last night, aTyr Pharma highlighted new external research that it said demonstrates the involvement of Neuropilin biology in SARS-CoV-2 infection. The company noted that it is currently investigating Neuropilin-2 receptor biology as a novel target for new product candidates for a variety of diseases, including cancer and inflammatory disorders. The company's lead therapeutic candidate, ATYR1923, selectively binds to NRP2 and is currently in clinical development for inflammatory lung diseases, including a Phase 2 study in patients with COVID-19 related severe respiratory complications. "We are particularly inspired by these independent findings and they further validate ATYR1923's potential to play a role as a treatment for COVID-19. As ATYR1923 is a selective modulator of NRP2 and dampens inflammatory response, the discovery of the Neuropilin domain as a binding site to the S1 protein significantly strengthens the hypothesis that ATYR1923 may have the potential to directly modulate SARS-CoV-2 infectivity and disease pathology," said Dr. Sanjay Shukla, President and CEO of aTyr.

ShowHide Related Items >><<
LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
03/02/20 Oppenheimer
aTyr Pharma initiated with an Outperform at Oppenheimer
LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

LIFE aTyr Pharma
$3.90 /

+0.015 (+0.39%)

Over a month ago
Hot Stocks
aTyr Pharma announces dosing of first patient in Phase 2 trial of ATYR1923 » 07:27
06/15/20
06/15
07:27
06/15/20
07:27
LIFE

aTyr Pharma

$3.48 /

+0.03 (+0.87%)

aTyr Pharma announced…

aTyr Pharma announced that it has dosed the first patient in a Phase 2 study evaluating its lead therapeutic candidate, ATYR1923, in COVID-19 patients with severe respiratory complications. The study is expected to enroll 30 patients at up to 10 centers in the U.S. and the company expects to have the majority of centers enrolling within the coming weeks. ATYR1923 is a potential first-in-class immunomodulator that has been shown preclinically to downregulate T-cell responses and improve inflammation and lung function. ATYR1923 is currently being evaluated in a Phase 1b/2a multi-center trial for patients with pulmonary sarcoidosis, a serious inflammatory lung disease. There is strong scientific rationale for the hypothesis that ATYR1923 may help regulate the excessive inflammatory response in the lungs, primarily driven by T-cells, seen in many COVID-19 patients. The Phase 2 clinical trial is a randomized, double blind, placebo-controlled study of ATYR1923 in hospitalized COVID-19 positive patients with severe respiratory complications who do not require mechanical ventilation. Patients enrolled in the trial will be assigned to one of three cohorts of 10 patients each. Patients will receive a single intravenous dose of either 1.0 or 3.0 mg/kg ATYR1923 or placebo. Patients will be followed for 60 days post treatment. The trial is designed to evaluate the preliminary safety and efficacy of ATYR1923 as compared to placebo through the assessment of key clinical outcome measures such as fever and hypoxia as well as inflammatory biomarkers.

ShowHide Related Items >><<
LIFE aTyr Pharma
$3.48 /

+0.03 (+0.87%)

LIFE aTyr Pharma
$3.48 /

+0.03 (+0.87%)

04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
03/02/20 Oppenheimer
aTyr Pharma initiated with an Outperform at Oppenheimer
LIFE aTyr Pharma
$3.48 /

+0.03 (+0.87%)

LIFE aTyr Pharma
$3.48 /

+0.03 (+0.87%)

Earnings
aTyr Pharma reports Q1 EPS 25c, consensus (18c) » 16:17
05/12/20
05/12
16:17
05/12/20
16:17
LIFE

aTyr Pharma

$3.77 /

-0.37 (-8.94%)

Reports Q1 revenue $8.07M…

Reports Q1 revenue $8.07M vs. $0 last year. "As the COVID-19 pandemic continues to unfold, we are abiding by government directives to keep our patients, investigators, site personnel and employees safe. While some of our investigational sites for our ongoing trial of ATYR1923 in pulmonary sarcoidosis have remained active, our timeline has been impacted by the pandemic and we expect a delay in the completion of enrollment. We are encouraged by our recent interactions with our investigators as they implement procedures to allow them to safely re-engage during the second quarter and complete our Phase 1b/2a trial study," said Dr. Sanjay S. Shukla, President and Chief Executive Officer of aTyr. "During the first quarter, we entered into a licensing agreement with Kyorin for ATYR1923 that generated an $8.0 million upfront payment and we also raised $20.7 million through a follow-on offering. These transactions strengthened our balance sheet, ending the first quarter of 2020 with approximately $50 million in cash. Additionally, we have looked to our own science to see how we may be able to contribute to the immediate need for effective treatments for COVID-19. We recently announced the FDA's acceptance of an investigational new drug (IND) application for a placebo-controlled Phase 2 study of ATYR1923 in COVID-19 patients with severe respiratory complications. The study will evaluate the safety and preliminary efficacy of ATYR1923 as compared to placebo. At this time, we are actively working to initiate investigational sites for this study."

ShowHide Related Items >><<
LIFE aTyr Pharma
$3.77 /

-0.37 (-8.94%)

LIFE aTyr Pharma
$3.77 /

-0.37 (-8.94%)

04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
03/02/20 Oppenheimer
aTyr Pharma initiated with an Outperform at Oppenheimer
LIFE aTyr Pharma
$3.77 /

-0.37 (-8.94%)

LIFE aTyr Pharma
$3.77 /

-0.37 (-8.94%)

Hot Stocks
aTyr Pharma announces publication of two abstracts on NRP2 » 08:50
05/05/20
05/05
08:50
05/05/20
08:50
LIFE

aTyr Pharma

$3.56 /

+0.14 (+4.09%)

aTyr Pharma announced…

aTyr Pharma announced that two abstracts originally accepted for presentation at the 2020 ATS International Conference will be published in the ATS journal, American Journal of Respiratory and Critical Care Medicine. One abstract characterizes the molecular basis for ATYR1923's immunomodulatory properties, including its ability to specifically and selectively bind to NRP2, a target that has been implicated in a broad range of immune-mediated diseases. The second abstract demonstrates that NRP2 is expressed on key immune cells in inflammatory conditions, including sarcoidosis granulomas, reinforcing its status as a key target in the treatment of immune-mediated diseases. P1173 - ATYR1923 Specifically Binds to Neuropilin-2, a Novel Therapeutic Target for the Treatment of Immune-Mediated Diseases: Neuropilin-2 is a pleiotropic cell surface receptor known to be expressed on a number of different immune cell types that plays a key role in regulating inflammatory responses. aTyr Pharma's lead clinical candidate, ATYR1923, is a fusion protein combining a novel immunomodulatory domain from histidyl-tRNA synthetase and a human IgG1 Fc. ATYR1923 has previously demonstrated potent immunomodulatory activity in vitro and in vivo. ATYR1923 specifically and selectively binds to NRP2 on the cell surface, which was discovered by cell microarray screening and confirmed by surface plasmon resonance and also by flow cytometry analysis of HEK293 cells over-expressing NRP2. Furthermore, ATYR1923 was also found to bind to cells that endogenously express NRP2 on the surface. These findings indicate that modulation of the NRP2 signaling pathway could be a novel therapeutic approach to immune-mediated diseases. ATYR1923 is currently being evaluated in a Phase 1b/2a study in patients with pulmonary sarcoidosis, an inflammatory disease which can result in lung fibrosis. P983 - Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune Cells: aTyr reports for the first time that NRP2 is expressed in samples obtained from lung and skin of sarcoidosis patients. More specifically, NRP2 expression was readily detectable within the granulomas in both skin and lung samples. In this abstract, the company demonstrates that NRP2 expression can be detected on key immune cells known to play an important role in inflammation and granuloma formation. These findings highlight the potential of ATYR1923 to exert its effect on various immune cells directly related to the pathology of the target patient population.

ShowHide Related Items >><<
LIFE aTyr Pharma
$3.56 /

+0.14 (+4.09%)

04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
03/02/20 Oppenheimer
aTyr Pharma initiated with an Outperform at Oppenheimer
Recommendations
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital » 14:48
04/30/20
04/30
14:48
04/30/20
14:48
LIFE

aTyr Pharma

$3.61 /

-0.08 (-2.17%)

, REGN

Regeneron

$524.70 /

+9.045 (+1.75%)

, SNY

Sanofi

$46.80 /

-0.5116 (-1.08%)

, GILD

Gilead

$81.71 /

-1.33 (-1.60%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah notes that early results from Regeneron (REGN) and Sanofi's (SNY) Kevzara and Gilead's (GILD) Remdesivir studies in COVID-19 patients have yielded somewhat promising results. However, the analyst believes there is still a need for additional "shots on goal." Accordingly, Jallah sees value in aTyr's (LIFE) pursuit of the development of ATYR1923 for COVID-19 patients, and believes that the company's preclinical data is supportive of its efficacy in a subgroup of "noncritical" patients. With ATYR1923's IND accepted, the analyst looks forward to the first COVID-19 patient being dosed. Jallah has a Buy rating and a $15 price target on aTyr's shares.

ShowHide Related Items >><<
LIFE aTyr Pharma
$3.61 /

-0.08 (-2.17%)

03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
03/04/20 Roth Capital
aTyr Pharma initiated with a Buy at Roth Capital
03/02/20 Oppenheimer
aTyr Pharma initiated with an Outperform at Oppenheimer
11/05/19 H.C. Wainwright
aTyr Pharma initiated with a Buy at H.C. Wainwright
REGN Regeneron
$524.70 /

+9.045 (+1.75%)

04/28/20 Citi
Regeneron downgraded to Neutral from Buy at Citi
04/27/20 RBC Capital
Regeneron's Libtayo looks competitive to Merck's Keytruda, says RBC Capital
04/27/20 Piper Sandler
Regeneron data updates had more good news than bad, says Piper Sandler
04/17/20 BMO Capital
Regeneron price target raised to $466 from $379 at BMO Capital
SNY Sanofi
$46.80 /

-0.5116 (-1.08%)

04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
04/21/20 Morgan Stanley
Sanofi price target lowered to EUR 101 from EUR 105 at Morgan Stanley
03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
GILD Gilead
$81.71 /

-1.33 (-1.60%)

04/30/20 Piper Sandler
Approval of Gilead's remdesivir 'all but final,' says Piper Sandler
04/29/20 Piper Sandler
Gilead's Chinese severe data 'definitely not a flop,' says Piper Sandler
04/29/20 Jefferies
Gilead remdesivir has become new standard-of-care for COVID-19, says Jefferies
04/29/20 Raymond James
'Let's not overreact' to Gilead's remdesivir data, says Raymond James

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.